| Metric | Q3 FY26 | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Other income | 0.2 | 0.5 | 0.4 |
| Total income | 0.2 | 0.5 | 0.4 |
| Net profit | 0.1 | 0.1 | 0.0 |
| Operating margin | 50.0% | 40.0% | 25.0% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, quarter on quarter | +0.00% |
|---|
BSE results filing, NSE: KANUNGO. Figures extracted from the filing.
Kanungo Financiers Ltd: key numbers
- Share price
- ₹14.60
- Market cap
- ₹6.77 Cr
- Revenue (annual)
- ₹0.00 Cr
- Net profit (annual)
- ₹0.63 Cr
- P/E (TTM)
- 11.4×Sector 21.5×
- Promoter holding
- 4.40%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Kanungo Financiers Ltd
All →Kanungo Financiers Board Meeting Outcome
Kanungo Financiers Limited approved its Q1 financial results and accepted the resignation of its statutory auditor, H S K & Co LLP.
Kanungo Financiers Annual General Meeting
Kanungo Financiers Limited has announced a book closure period from September 23, 2026, to September 29, 2026, for its upcoming Annual General Meeting.
Kanungo Financiers Board Meeting Outcome
Kanungo Financiers announced its AGM date, registered office relocation to Maharashtra, and appointments of new Independent Directors and Statutory Auditors.
Kanungo Financiers Board Meeting Date
Kanungo Financiers Limited scheduled a board meeting on September 4, 2026, to discuss the upcoming Annual General Meeting, Director's Report, and other administrative matters.
Kanungo Financiers Other Announcement
Kanungo Financiers Ltd announced the proposed appointment of M/s. Suvarna & Katdare as statutory auditors, subject to upcoming board and shareholder approval.
Kanungo Financiers Annual General Meeting
Kanungo Financiers held an EOGM approving capital expansion, acquisitions of two private companies, and the appointment of a new Managing Director.